Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug

Journal of Medicinal Chemistry

Volumn 55, Issue 18, 2012, Pages 8038-8046

  Baiz, Daniele ^a   Pinder, Tanya A ^b   Hassan, Sazzad ^a   Karpova, Yelena ^a   Salsbury, Freddie ^b   Welker, Mark E ^b   Kulik, George ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4(2 MORPHOLINO 4 OXO 4H CHROMEN 8 YL) BENZYL 2 AMINO 4 METHYLPENTANOATE; MU LEUCYLGLUTAMYLHISTIDYLSERYLSERYLLYSYLLEUCYLGLUTAMINYLLEUCINE; MU LEUCYLGLUTAMYLHISTIDYLSERYLSERYLLYSYLLEUCYLGLUTAMINYLLEUCINE 8[4 (HYDROXYMETHYL) PHENYL] 2 MORPHOLINO 4H CHROMEN 4 ONE; PEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN CLEAVAGE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHEMISTRY TECHNIQUES, SYNTHETIC; CHROMONES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MALE; MOLECULAR DOCKING SIMULATION; MORPHOLINES; OLIGOPEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84866855760     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300881a     Document Type: Article

References (30)

1. Wang, X.; Ma, D.; Olson, W. C.; Heston, W. D. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen Mol. Cancer Ther. 2011, 10, 1728-1739
2. Sarker, D.; Reid, A. H. M.; Yap, T. A.; de Bono, J. S. Targeting the PI3K/AKT pathway for the treatment of prostate cancer Clin. Cancer Res. 2009, 15, 4799-4805
3. Cohen, M. B.; Rokhlin, O. W. Mechanisms of prostate cancer cell survival after inhibition of AR expression J. Cell Biochem. 2009, 106, 363-371
4. Morgan, T. M.; Koreckij, T. D.; Corey, E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway Curr. Cancer Drug Targets 2009, 9, 237-249
5. Mazzoletti, M.; Bortolin, F.; Brunelli, L.; Pastorelli, R.; Di Giandomenico, S.; Erba, E.; Ubezio, P.; Broggini, M. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates Cancer Res. 2011, 71, 4573-4584
6. Erlich, R. B.; Kherrouche, Z.; Rickwood, D.; Endo-Munoz, L.; Cameron, S.; Dahler, A.; Hazar-Rethinam, M.; de Long, L. M.; Wooley, K.; Guminski, A.; Saunders, N. A. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma Br. J. Cancer 2012, 106, 107-115
7. Bjork, T.; Lilja, H.; Christensson, A. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer BJU Int. 1999, 84, 1021-1027
8. LeBeau, A. M.; Singh, P.; Isaacs, J. T.; Denmeade, S. R. Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity Biochemistry 2009, 48, 3490-3496
9. Evans-Axelsson, S.; Ulmert, D.; Orbom, A.; Peterson, P.; Nilsson, O.; Wennerberg, J.; Strand, J.; Wingardh, K.; Olsson, T.; Hagman, Z.; Tolmachev, V.; Bjartell, A.; Lilja, H.; Strand, S. E. Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone Cancer Biother. Radiopharm. 2012, 27, 243-251
10. Coombs, G. S.; Bergstrom, R. C.; Pellequer, J. L.; Baker, S. I.; Navre, M.; Smith, M. M.; Tainer, J. A.; Madison, E. L.; Corey, D. R. Substrate specificity of prostate-specific antigen (PSA) Chem. Biol. 1998, 5, 475-488
11. LeBeau, A. M.; Banerjee, S. R.; Pomper, M. G.; Mease, R. C.; Denmeade, S. R. Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer Bioorg. Med. Chem. 2009, 17, 4888-4893
12. Vlahos, C. J.; Matter, W. F.; Brown, R. F.; Traynor-Kaplan, A. E.; Heyworth, P. G.; Prossnitz, E. R.; Ye, R. D.; Marder, P.; Schelm, J. A.; Rothfuss, K. J.; Serlin, B. S.; Simpson, P. J. Investigation of neutrophil signal transduction using a specific inhibitor of phosphatidylinositol 3-kinase J. Immunol. 1995, 154, 2413-2422
13. Holmes, D. PI3K pathway inhibitors approach junction Nat. Rev. Drug Discov. 2011, 10, 563-564
14. Garlich, J. R.; De, P.; Dey, N.; Su, J. D.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G. B.; Kundra, V.; Shu, H. K.; Peng, Q.; Durden, D. L. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity Cancer Res. 2008, 68, 206-215
15. Gharbi, S. I.; Zvelebil, M. J.; Shuttleworth, S. J.; Hancox, T.; Saghir, N.; Timms, J. F.; Waterfield, M. D. Exploring the specificity of the PI3K family inhibitor LY294002 Biochem. J. 2007, 404, 15-21
16. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a lamarckian genetic algorithm and and empirical binding free energy function J. Comput. Chem. 1998, 1639-1662
17. Abbott, B. M.; Thompson, P. E. Synthetic studies of the phosphatidylinositol 3-kinase inhibitor LY294002 and related analogues Aust. J. Chem. 2003, 56, 1099-1106
18. Zha, J.; Harada, H.; Yang, E.; Jockel, J.; Korsmeyer, S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell 1996, 87, 619-628
19. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 1997, 91, 231-241
20. del Peso, L.; Gonzalez-Garcia, M.; Page, C.; Herrera, R.; Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt Science 1997, 278, 687-689
21. Sastry, K. S. R.; Karpova, Y.; Kulik, G. Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways J. Biol. Chem. 2006, 281, 27367-27377
22. Khan, S. R.; Denmeade, S. R. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts Prostate 2000, 45, 80-83
23. Brady, S. F.; Pawluczyk, J. M.; Lumma, P. K.; Feng, D. M.; Wai, J. M.; Jones, R.; DeFeo-Jones, D.; Wong, B. K.; Miller-Stein, C.; Lin, J. H.; Oliff, A.; Freidinger, R. M.; Garsky, V. M. Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity J. Med. Chem. 2002, 45, 4706-4715
24. Denmeade, S. R.; Jakobsen, C. M.; Janssen, S.; Khan, S. R.; Garrett, E. S.; Lilja, H.; Christensen, S. B.; Isaacs, J. T. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer J. Natl. Cancer Inst. 2003, 95, 990-1000
25. Rudner, J.; Ruiner, C. E.; Handrick, R.; Eibl, H. J.; Belka, C.; Jendrossek, V. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation Radiat. Oncol. 2010, 5, 108
26. Ellwood-Yen, K.; Keilhack, H.; Kunii, K.; Dolinski, B.; Connor, Y.; Hu, K.; Nagashima, K.; O'Hare, E.; Erkul, Y.; Di Bacco, A.; Gargano, D.; Shomer, N. H.; Angagaw, M.; Leccese, E.; Andrade, P.; Hurd, M.; Shin, M. K.; Vogt, T. F.; Northrup, A.; Bobkova, E. V.; Kasibhatla, S.; Bronson, R. T.; Scott, M. L.; Draetta, G.; Richon, V.; Kohl, N.; Blume-Jensen, P.; Andersen, J. N.; Kraus, M. PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models Cancer Res. 2011, 71, 3052-3065
27. Yuan, J.; Mehta, P. P.; Yin, M. J.; Sun, S.; Zou, A.; Chen, J.; Rafidi, K.; Feng, Z.; Nickel, J.; Engebretsen, J.; Hallin, J.; Blasina, A.; Zhang, E.; Nguyen, L.; Sun, M.; Vogt, P. K.; McHarg, A.; Cheng, H.; Christensen, J. G.; Kan, J. L.; Bagrodia, S. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity Mol. Cancer Ther. 2011, 10, 2189-2199
28. Brachmann, S. M.; Hofmann, I.; Schnell, C.; Fritsch, C.; Wee, S.; Lane, H.; Wang, S.; Garcia-Echeverria, C.; Maira, S. M. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 22299-22304
29. Wallin, J. J.; Edgar, K. A.; Guan, J.; Berry, M.; Prior, W. W.; Lee, L.; Lesnick, J. D.; Lewis, C.; Nonomiya, J.; Pang, J.; Salphati, L.; Olivero, A. G.; Sutherlin, D. P.; O'Brien, C.; Spoerke, J. M.; Patel, S.; Lensun, L.; Kassees, R.; Ross, L.; Lackner, M. R.; Sampath, D.; Belvin, M.; Friedman, L. S. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway Mol. Cancer Ther. 2011, 10, 2426-2436
30. Sastry, K. S. R.; Karpova, Y.; Prokopovich, S.; Smith, A. J.; Essau, B.; Gersappe, A.; Carson, J. P.; Weber, M. J.; Register, T. C.; Chen, Y. Q.; Penn, R. B.; Kulik, G. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation J. Biol. Chem. 2007, 282, 14094-14100